|
|
| Zeile 8: |
Zeile 8: |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32379112|t=2020. Novel Coronavirus COVID-19: Current Evidence and Evolving Strategies |pdf=|usr=}}
| |
| − | {{tp|p=32348588|t=2020. COVID-19 diagnosis and management: a comprehensive review |pdf=|usr=}}
| |
| − | {{tp|p=32232980|t=ä. COVID?19 epidemic: Disease characteristics in children |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 27: |
Zeile 23: |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{ttp|p=32357381|t=2020. Respiratory sampling for severe acute respiratory syndrome coronavirus 2: An Overview |pdf=|usr=}}
| |
| − | {{tp|p=32329102|t=2020. Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment |pdf=|usr=}}
| |
| − | {{tp|p=32295895|t=2020. Comparison of Copan ESwab and FLOQSwab for COVID-19 Diagnosis: Working around a Supply Shortage |pdf=|usr=}}
| |
| − | {{tp|p=32380382|t=ä. Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays |pdf=|usr=}}
| |
| − | {{ttp|p=32357377|t=2020. Performing the nasopharyngeal and oropharyngeal swab for 2019-novel coronavirus (SARS-CoV-2) safely: How to dress, undress, and technical notes |pdf=|usr=}}
| |
| − | {{ttp|p=32352180|t=2020. COVID-19: Nasal and oropharyngeal swab |pdf=|usr=}}
| |
| − | {{tp|p=32329138|t=2020. Who should perform the rhinopharyngeal swab in COVID-19 positive patients?|pdf=|usr=}}
| |
| − | {{tp|p=32356761|t=2020. Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management |pdf=|usr=}}
| |
| − | {{ttp|p=32311826|t=2020. COVID-19 and the clinical hematology laboratory |pdf=|usr=}}
| |
| − | {{ttp|p=32245835|t=2020. Laboratory Diagnosis of COVID-19: Current Issues and Challenges |pdf=|usr=}}
| |
| − | {{tp|p=32349033|t=2020. Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32366669|t=2020. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test |pdf=|usr=}}
| |
| − | {{tp|p=32229605|t=2020. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 46: |
Zeile 29: |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{ttp|p=32305937|t=2020. Review of Artificial Intelligence Techniques in Imaging Data Acquisition, Segmentation and Diagnosis for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32217900|t=2020. High-Resolution Computed Tomography Manifestations of 5 Pediatric Patients With 2019 Novel Coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32349032|t=2020. Use of Radiographic Features in COVID-19 Diagnosis: Challenges and Perspectives |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| Zeile 83: |
Zeile 62: |
| | ---- | | ---- |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32364407|t=2020. COVID-19 Lung Injury Is Different From High Altitude Pulmonary Edema (Re: High Alt Med Biol Epub ahead of print ; DOI: 10 1089/ham 2020 0055) |pdf=|usr=}}
| |
| − | {{tp|p=32281877|t=2020. COVID-19 Lung Injury is Not High Altitude Pulmonary Edema |pdf=|usr=}}
| |
| − | {{tp|p=32374419|t=2020. Pulmonary Pathology of Early Phase COVID-19 Pneumonia in a Patient with a Benign Lung Lesion |pdf=|usr=}}
| |
| − | {{ttp|p=32364264|t=2020. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction |pdf=|usr=}}
| |
| − | {{ttp|p=32371536|t=2020. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32198191|t=2020. Autopsy in suspected COVID-19 cases |pdf=|usr=}}
| |
| − | {{tp|p=32358895|t=2020. Histological pattern in Covid-19 induced viral rash |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 119: |
Zeile 91: |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32354798|t=2020. Acute myocardial injury is common in patients with covid-19 and impairs their prognosis |pdf=|usr=}}
| |
| − | {{tp|p=32282502|t=ä. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32306491|t=2020. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review |pdf=|usr=}}
| |
| − | {{tp|p=32270559|t=2020. Cardiac and arrhythmic complications in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32232979|t=ä. Analysis of heart injury laboratory parameters in 273 COVID?19 patients in one hospital in Wuhan, China |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32342566|t=2020. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases |pdf=|usr=}}
| |
| − | {{tp|p=32317428|t=2020. What ophthalmologists should know about conjunctivitis in the COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32366336|t=2020. Olfactory and gustatory dysfunction caused by SARS-CoV-2: comparison with cases of infection with influenza and other viruses |pdf=|usr=}}
| |
| − | {{tp|p=32342636|t=2020. Potential pathogenesis of ageusia and anosmia in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32329222|t=2020. Self-reported olfactory loss associates with outpatient clinical course in Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32301284|t=2020. Smell dysfunction: a biomarker for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | {{tp|p=32380219|t=ä. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France |pdf=|usr=}}
| |
| − | {{tp|p=32380215|t=ä. Reply to ?Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients?: discussing specificity |pdf=|usr=}}
| |
| − | {{tp|p=32358979|t=2020. Diffuse cutaneous manifestation in a new mother with COVID-19 (SARS-Cov-2) |pdf=|usr=}}
| |
| − | {{tp|p=32329897|t=2020. Chilblain-like lesions on feet and hands during the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32366113|t=2020. Foot Manifestations in a COVID-19 Positive Patient: A Case Study |pdf=|usr=}}
| |
| − | {{tp|p=32310671|t=2020. Addressing the Question of Dermatologic Manifestations of SARS-CoV-2 Infection in the Lower Extremities: A Closer Look at the Available Data and its Implications |pdf=|usr=}}
| |
| − | {{tp|p=32365277|t=2020. New emerging dermatological symptoms in coronavirus pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32301221|t=2020. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity |pdf=|usr=}}
| |
| − | {{tp|p=32363963|t=2020. Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report |pdf=|usr=}}
| |
| − | {{ttp|p=32378770|t=2020. Drug-induced vasculitis in a patient with COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32378747|t=2020. Symmetric cutaneous vasculitis in COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32378743|t=2020. Acro-ischemia in hospitalized COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32359182|t=2020. Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus |pdf=|usr=}}
| |
| − | {{tp|p=32359180|t=2020. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection |pdf=|usr=}}
| |
| − | {{ttp|p=32358895|t=2020. Histological pattern in Covid-19 induced viral rash |pdf=|usr=}}
| |
| − | {{tp|p=32215952|t=2020. Cutaneous manifestations in COVID-19: a first perspective |pdf=|usr=}}
| |
| − | {{ttp|p=32339344|t=2020. Vascular skin symptoms in COVID-19: a french observational study |pdf=|usr=}}
| |
| − | {{tp|p=32330340|t=2020. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome |pdf=|usr=}}
| |
| − | {{tp|p=32330339|t=2020. Cutaneous manifestation of COVID-19 in images: a case report |pdf=|usr=}}
| |
| − | {{tp|p=32330336|t=2020. SARS-CoV-2 infection presenting as a febrile rash |pdf=|usr=}}
| |
| − | {{tp|p=32330334|t=2020. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients |pdf=|usr=}}
| |
| − | {{tp|p=32330324|t=2020. Acral cutaneous lesions in the time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32330322|t=2020. Did Whatsapp((R)) reveal a new cutaneous COVID-19 manifestation?|pdf=|usr=}}
| |
| − | {{tp|p=32329915|t=2020. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32294273|t=2020. Urticarial eruption in COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32294271|t=2020. COVID-19 and Cutaneous manifestations |pdf=|usr=}}
| |
| − | {{tp|p=32294270|t=2020. Viral exanthem in COVID-19, a clinical enigma with biological significance |pdf=|usr=}}
| |
| − | {{tp|p=32294264|t=2020. Cutaneous manifestations in COVID-19: a new contribution |pdf=|usr=}}
| |
| − | {{tp|p=32294259|t=2020. A distinctive skin rash associated with Coronavirus Disease 2019 ?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32241899|t=2020. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32139552|t=2020. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32327526|t=2020. Severe liver failure during SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32279064|t=2020. Coronavirus Disease (COVID-19) and the Gastrointestinal System in Children |pdf=|usr=}}
| |
| − | {{tp|p=32267098|t=2020. Digestive system involvement of novel coronavirus infection: Prevention and control infection from a gastroenterology perspective |pdf=|usr=}}
| |
| − | {{tp|p=32215956|t=2020. Covid-19 and the digestive system |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Kidney, urology]]''' | | *'''[[Kidney, urology]]''' |
| − | {{ttp|p=32371536|t=2020. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32366514|t=2020. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology |pdf=|usr=}}
| |
| − | {{tp|p=32345702|t=2020. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32376422|t=ä. Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern |pdf=|usr=}}
| |
| − | {{tp|p=32380214|t=ä. Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32245909|t=2020. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis |pdf=|usr=}}
| |
| − | {{tp|p=32312788|t=2020. Covid-19 infection in Crohn s disease under treatment with adalimumab |pdf=|usr=}}
| |
| − | {{tp|p=32307955|t=2020. COVID-19, THE KIDNEY AND HYPERTENSION |pdf=|usr=}}
| |
| − | {{tp|p=32220017|t=2020. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient |pdf=|usr=}}
| |
| − | {{tp|p=32340044|t=2020. The ACE-2 in COVID-19: Foe or Friend?|pdf=|usr=}}
| |
| − | {{tp|p=32208987|t=2020. Renin-angiotensin system (RAS) blockers and the COVID-19 pandemic: at present there is no evidence to abandon RAS blockers |pdf=|usr=}}
| |
| − | {{tp|p=32367746|t=2020. ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective |pdf=|usr=}}
| |
| − | {{tp|p=32348166|t=2020. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study |pdf=|usr=}}
| |
| − | {{tp|p=32324897|t=2020. Management of the first patient with confirmed COVID-19 in pregnancy in India: From guidelines to frontlines |pdf=|usr=}}
| |
| − | {{tp|p=32330287|t=2020. A systematic scoping review of COVID-19 during pregnancy and childbirth |pdf=|usr=}}
| |
| − | {{tp|p=32270479|t=2020. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32271947|t=2020. Delivery in pregnant women infected with SARS-CoV-2: A fast review |pdf=|usr=}}
| |
| − | {{tp|p=32369616|t=2020. Critically ill pregnant patient with COVID-19 and neonatal death within two hours of birth |pdf=|usr=}}
| |
| − | {{tp|p=32310015|t=2020. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature |pdf=|usr=}}
| |
| − | {{tp|p=32255507|t=2020. COVID-19 and Older Adults: What We Know |pdf=|usr=}}
| |
| − | {{tp|p=32301766|t=ä. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2 |pdf=|usr=}}
| |
| − | {{tp|p=32376098|t=ä. A MULTINATIONAL REPORT TO CHARACTERISE SARS-CoV-2 INFECTION IN PEOPLE WITH CYSTIC FIBROSIS |pdf=|usr=}}
| |
| − | {{tp|p=32371817|t=2020. Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?|pdf=|usr=}}
| |
| − | {{tp|p=32371814|t=2020. Response to four comments on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?? |pdf=|usr=}}
| |
| − | {{tp|p=32371812|t=2020. COVID-19, hypertension and angiotensin receptor-blocking drugs |pdf=|usr=}}
| |
| − | {{tp|p=32371810|t=2020. Comment on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?? |pdf=|usr=}}
| |
| − | {{tp|p=32345701|t=2020. The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32317402|t=2020. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York |pdf=|usr=}}
| |
| − | {{tp|p=32312797|t=2020. COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?|pdf=|usr=}}
| |
| − | {{tp|p=32253888|t=2020. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection |pdf=|usr=}}
| |
| − | {{tp|p=32351121|t=2020. Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder |pdf=|usr=}}
| |
| − | {{tp|p=32353193|t=2020. Is the type of diabetes treatment relevant to outcome of COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32162476|t=2020. Diabetes and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32379925|t=2020. Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient |pdf=|usr=}}
| |
| − | {{tp|p=32379913|t=2020. Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs |pdf=|usr=}}
| |
| − | {{tp|p=32358791|t=2020. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor |pdf=|usr=}}
| |
| − | {{tp|p=32330323|t=2020. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports |pdf=|usr=}}
| |
| − | {{tp|p=32294258|t=2020. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor |pdf=|usr=}}
| |
| − | {{tp|p=32195824|t=2020. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32242993|t=2020. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk |pdf=|usr=}}
| |
| − | {{tp|p=32354293|t=2020. Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[The morbid survivor]]''' | | *'''[[The morbid survivor]]''' |
| Zeile 244: |
Zeile 119: |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32298218|t=2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 |pdf=|usr=}}
| |
| − | {{tp|p=32317431|t=2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |pdf=|usr=}}
| |
| − | {{tp|p=32370727|t=2020. SARS-CoV-2 & Covid-19: Key-Roles of the Renin-Angiotensin System / Vitamin D Impacting Drug and Vaccine Developments |pdf=|usr=}}
| |
| − | {{ttp|p=32377694|t=2020. Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review) |pdf=|usr=}}
| |
| − | {{tp|p=32338559|t=2020. Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?|pdf=|usr=}}
| |
| − | {{tp|p=32319538|t=2020. Zinc and respiratory tract infections: Perspectives for COVID19 (Review) |pdf=|usr=}}
| |
| − | {{tp|p=32310190|t=2020. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32347747|t=2020. Can melatonin reduce the severity of COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32268052|t=2020. Vitamin D, Covid-19 and Children |pdf=|usr=}}
| |
| − | {{tp|p=32268051|t=2020. Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32338164|t=2020. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective |pdf=|usr=}}
| |
| − | {{tp|p=32306860|t=2020. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations |pdf=|usr=}}
| |
| − | {{tp|p=32306822|t=2020. Peptide-like and small-molecule inhibitors against Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32340551|t=2020. Natural products may interfere with SARS-CoV-2 attachment to the host cell |pdf=|usr=}}
| |
| − | {{tp|p=32329419|t=2020. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach |pdf=|usr=}}
| |
| − | {{tp|p=32329408|t=2020. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease |pdf=|usr=}}
| |
| − | {{tp|p=32362235|t=2020. Understanding the binding affinity of ''noscapines'' with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures |pdf=|usr=}}
| |
| − | {{tp|p=32362243|t=2020. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target |pdf=|usr=}}
| |
| − | {{tp|p=32364041|t=2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32364011|t=2020. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication |pdf=|usr=}}
| |
| − | {{tp|p=32362217|t=2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria |pdf=|usr=}}
| |
| − | {{tp|p=32362245|t=2020. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study |pdf=|usr=}}
| |
| − | {{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}}
| |
| − | {{tp|p=32340562|t=2020. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32376368|t=ä. Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach |pdf=|usr=}}
| |
| − | {{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}}
| |
| − | {{tp|p=32171193|t=2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies |pdf=|usr=}}
| |
| − | {{tp|p=32367767|t=2020. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants |pdf=|usr=}}
| |
| − | {{tp|p=32238094|t=2020. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach |pdf=|usr=}}
| |
| − | {{tp|p=32345140|t=2020. Stilbene-based natural compounds as promising drug candidates against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32266867|t=2020. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain) |pdf=|usr=}}
| |
| − | {{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32349031|t=2020. Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32173110|t=2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32379348|t=2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 293: |
Zeile 132: |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32246972|t=2020. Ultraviolet germicidal irradiation: Possible method for respirator disinfection to facilitate reuse during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32319881|t=2020. May hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection?|pdf=|usr=}}
| |
| − | {{tp|p=32299521|t=2020. Environmental cleaning is effective for the eradication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in contaminated hospital rooms: A patient from the Diamond Princess cruise ship |pdf=|usr=}}
| |
| − | {{tp|p=32337516|t=2020. Use of free CAD design software for 3D printing individualized face masks based on face scans |pdf=|usr=}}
| |
| − | {{tp|p=32379379|t=2020. Treatment of nasal bridge ulceration related to protective measures for the COVID-19 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32377058|t=ä. Sustainability of Coronavirus on different surfaces |pdf=|usr=}}
| |
| − | {{tp|p=32167245|t=ä. Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and meta?analysis |pdf=|usr=}}
| |
| − | {{tp|p=32362062|t=2020. Occupational skin conditions on the frontline: A survey among 484 Chinese healthcare professionals caring for Covid-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32302444|t=2020. Skin Reactions to Non-glove Personal Protective Equipment: An Emerging Issue in the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32302449|t=2020. Covid-19: countermeasure for N95 mask-induced pressure sore |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32358855|t=2020. Tracheostomy during COVID-19 pandemic-Novel approach |pdf=|usr=}}
| |
| − | {{tp|p=32298034|t=2020. How to avoid nosocomial spread during tracheostomy for COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32270574|t=2020. Improving staff safety during tracheostomy in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32348600|t=2020. Bronchoscopy, laryngoscopy, and esophagoscopy during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32348582|t=2020. Clinical trials during COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32365278|t=2020. Management of COVID-19 in hemodialysis patients: The Genoa experience |pdf=|usr=}}
| |
| − | {{tp|p=32321619|t=2020. How we mitigate and contain COVID-19 outbreak in hemodialysis center (HD): lessons and experiences |pdf=|usr=}}
| |
| − | {{tp|p=32350871|t=2020. Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32196655|t=2020. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection |pdf=|usr=}}
| |
| − | {{tp|p=32362244|t=2020. Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel |pdf=|usr=}}
| |
| − | {{tp|p=32345922|t=ä. Single-use Bronchoscopes: Applications in COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32300070|t=2020. Counterpoint: Twice-Weekly Hemodialysis Should Be an Approach of Last Resort Even in Times of Dialysis Unit Stress |pdf=|usr=}}
| |
| − | {{tp|p=32300069|t=2020. Twice-Weekly Hemodialysis Is an Option for Many Patients in Times of Dialysis Unit Stress |pdf=|usr=}}
| |
| − | {{tp|p=32267782|t=2020. Challenges Faced by Medical Journals During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32343162|t=2020. Conducting clinical trials during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32280138|t=2020. Perfusion?s Role in Responding to the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32372533|t=2020. Fecal testing for SARS-CoV-2 in patients undergoing elective lower gastrointestinal endoscopy is advised |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| | | | |
| Zeile 347: |
Zeile 156: |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32325535|t=2020. Covid-19 in Fluchtlingsunterkunften: OGD jetzt weiter starken |pdf=|usr=}}
| |
| − | {{tp|p=32338071|t=2020. Racial Capitalism: A Fundamental Cause of Novel Coronavirus (COVID-19) Pandemic Inequities in the United States |pdf=|usr=}}
| |
| − | {{ttp|p=32378252|t=2020. A phased approach to unlocking during the COVID-19 pandemic-Lessons from trend analysis |pdf=|usr=}}
| |
| − | {{tp|p=32301199|t=2020. Estimation of basic reproduction number for COVID-19 and the reasons for its differences |pdf=|usr=}}
| |
| − | {{tp|p=32141624|t=ä. Transmission dynamics of the COVID?19 outbreak and effectiveness of government interventions: A data?driven analysis |pdf=|usr=}}
| |
| − | {{tp|p=32134116|t=ä. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID?19) implicate special control measures |pdf=|usr=}}
| |
| | | | |
| | | | |
